CFCM / EVIDENCE
Evidence
Primary sources. Clear boundaries. Independent analysis.
CFCM analysis
Editorial interpretations of primary evidence. These articles are not themselves primary research.
Flow Cytometry as a Cell-Therapy Release Assay ↗
Flow can contribute to product characterisation and release testing. Identity, viability and potency must remain distinct claims.
CFCM ANALYSISClinical Flow AI Under the EU AI Act ↗
The regulatory question begins with intended purpose and the product's role. An accuracy score cannot determine the legal classification.
CFCM ANALYSISSynthetic Controls, Spectral MRD and Reproducibility ↗
Reference materials and clinical spectral MRD are advancing in parallel. Their convergence needs evidence at the assay level.
CFCM ANALYSISThe 40-Colour Race May Be Ending ↗
The useful question is how much reliable biological information a workflow delivers. Colour count alone cannot answer it.
CFCM ANALYSISHas Clinical Spectral Flow Cytometry Finally Arrived? ↗
Clinical spectral cytometry is moving from technical possibility toward MRD and other validated clinical workflows.
CFCM ANALYSISDeep Learning for Mature B-Cell Neoplasms Reaches Clinical-Scale Data ↗
What clinical-scale deep learning studies mean for automated analysis of mature B-cell neoplasms by flow cytometry.
Read the source in context
Source types remain distinct: guidelines, standards, original research, reviews, consensus, regulatory material, manufacturer documentation and abstracts or preprints.